Trial Profile
A Phase 3, Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 14 Mar 2024
Price :
$35
*
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Sponsors BioMarin Pharmaceutical
- 12 Mar 2024 According to a BioMarin Pharmaceutical media release, the results from this trial will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024.
- 30 Jun 2022 Planned End Date changed from 1 Dec 2024 to 1 Jun 2031.
- 30 Jun 2022 Planned primary completion date changed from 1 Oct 2024 to 1 Jun 2031.